Table 1. Percentage of patients in each... | American Society of Hematology

Table 1.

Percentage of patients in each group achieving good response to imatinib as defined by 2-log reduction by 3 months and 3-log reduction by 12 months

	2-log reduction in BCR-ABL by 3 mo	3-log reduction in BCR-ABL by 12 mo
Overall IC50^imatinib
Low, %, n = 36	36	47
High, %, n = 26	8	23
P	.01	.03
Overall Sokal score
Low, %, n = 28	29	54
High, %, n = 31	16	19
P	> .05	.008
Low Sokal score only
Low IC50^imatinib, %, n = 15	53	73
High IC50^imatinib, %, n = 13	0	31
P	.002	.023
High Sokal score only
Low IC50^imatinib, %, n = 19	16	26
High IC50^imatinib, %, n = 12	17	8
P	> .05	> .05

	2-log reduction in BCR-ABL by 3 mo	3-log reduction in BCR-ABL by 12 mo
Overall IC50^imatinib
Low, %, n = 36	36	47
High, %, n = 26	8	23
P	.01	.03
Overall Sokal score
Low, %, n = 28	29	54
High, %, n = 31	16	19
P	> .05	.008
Low Sokal score only
Low IC50^imatinib, %, n = 15	53	73
High IC50^imatinib, %, n = 13	0	31
P	.002	.023
High Sokal score only
Low IC50^imatinib, %, n = 19	16	26
High IC50^imatinib, %, n = 12	17	8
P	> .05	> .05